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PATIENT PREFERENCES AND STATED ADHERENCE FOR HEPATITIS C
VIRUS TREATMENTS
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1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, 
Switzerland, 3Human Genome Sciences, Inc, Rockville, MD, USA
OBJECTIVES: To estimate patient preferences for attributes of hepatitis C virus 
(HCV) treatments and the effect of product attributes on stated medication adherence.
METHODS: HCV patients,18 years and older completed an online survey instrument
that included 9 conjoint choice-format trade-off tasks. Subjects chose among pairs of 
hypothetical medication alternatives, each deﬁ ned by chance that the medicine will 
eliminate the virus completely (EFFICACY), injection frequency, duration of ﬂ u-like 
symptoms after each injection, injection device (DEVICE), average number of days of 
work missed each week (LOST WORK DAYS), probability of reversible hair thinning 
while on treatment (HAIR THINNING), and probability of developing clinical depres-
sion while on treatment (DEPRESSION). Subjects also answered 3 rating questions 
assessing how often people with HCV would miss or skip doses of medications with
different characteristics. We used mixed-logit methods to estimate mean relative 
importance weights for each attribute. We used a Heckman two-stage model to esti-
mate ﬁ rst the effect of subject characteristics the effect of medication attributes on 
non-adherence. RESULTS: A total of 143 subjects completed the survey. In the model, 
number of ﬂ u days (FLU DAYS) was speciﬁ ed as injection frequency multiplied by the 
duration of ﬂ u-like symptoms after every injection. EFFICACY was the most impor-
tant attribute. The remaining attributes were ranked in order of importance as follows:
DEPRESSION, FLU DAYS, LOST WORK DAYS, HAIR THINNING, and DEVICE. 
Subjects with prior experience were less likely to be non-adherent and increases in the
number of ﬂ u days increased the likelihood of non-adherence. CONCLUSIONS: The
results of this study demonstrate that efﬁ cacy is the most important medication attri-
bute to patients but medication side effects like the number of ﬂ u days affect stated 
medication adherence. Reducing the number of ﬂ u days by reducing the frequency of 
injections or the duration of ﬂ u-like symptoms after each injection may increase 
medication adherence.
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ASSESSING DISEASE BURDEN FOR MEASLES USING A CLINICAL AND
HEALTH OUTCOMES APPROACH: A FOCUS ON LOWER-INCOME 
COUNTRIES
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OBJECTIVES: We developed a measles health outcomes model for lower-income
countries for use in cost-effectiveness (CE) and policy models assessing measles inter-
ventions as well as long-term investment decisions for potential innovations. 
METHODS: The clinical, HO, and CE literature for measles was evaluated, including 
methodological issues related to using disability-adjusted life years (DALYs) and/or 
quality-adjusted life years (QALYs) to assess disease burden. We constructed a descrip-
tive clinical model of measles infection depicting clinical sequelae as a health outcomes 
tree. DALY and QALY weights were estimated from the literature. Morbidity and
mortality were considered using two alternative approaches, one based on an aggre-
gate estimate of measles-associated disability and the other based on a detailed con-
sideration of these sequelae. Deaths from measles were assumed to occur at 2.5 years
of age. Aggregate impacts were assessed using estimates from an infectious disease
model applied to 6 developing countries between 2010–2029. RESULTS: A focus on 
DALYs in the measles global health literature led us to concentrate on the aggregate 
and sequelae-based DALY estimates. India and Nigeria were estimated to have the
greatest avoidance in life years lost and morbidity-adjusted life years (DALYs avoided; 
QALYs gained) due to reduced measles outbreaks, partly due to population size (e.g.,
170,000 and 43,000 DALYs avoided, respectively; 3% disc. rt.). For all countries,
under various scenarios and discount rates for both approaches, the mortality effect 
dominated morbidity effects and accounted for approximately 90–99% of the overall 
DALY burden. CONCLUSIONS: Evaluating morbidity and mortality outcomes of 
measles in developing nations is complex and involves substantial uncertainty. LYL 
effects dominated disability effects in resource-limited countries, even with higher rates
of complications from measles (50–80% of cases). Several challenges include limited
clinical and economic data, unavailable country-speciﬁ c health-state weights, and 
sparse HO data for vulnerable sub-populations, such as those with HIV/AIDS or that
are malnourished.
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MEASUREMENT OF SYMPTOMS AND IMPACT OF INFLUENZA: 
DEVELOPMENT OF THE SYMPTOM INTENSITY AND IMPACT OF
INFLUENZA QUESTIONNAIRE (FLU-IIQ)
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OBJECTIVES: The assessment of new agents designed to reduce symptom severity 
and impact of inﬂ uenza requires accurate and valid assessment of the onset, duration
and resolution of the illness within clinical trials. New agents have a range of potential
effects on individual susceptibility and impact of the illness. A Patient-Reported
Outcome measure including two scales (inﬂ uenza symptom severity and impact on
well-being) was developed for use across clinical settings. METHODS: Items were
generated directly from subjects (n  16) with inﬂ uenza through Concept Mapping, 
conﬁ rmed by expert input (n  7) and supported by the review of the literature. 
The ﬁ nal questionnaire was administered to 311 subjects experiencing inﬂ uenza like 
illness, including 22% with laboratory-conﬁ rmed inﬂ uenza infection, presenting to 
clinicians across 25 USA sites. Items properties and scales were investigated using
descriptive statistics, Item Response Theory (IRT), Conﬁ rmatory Factor Analysis 
(CFA), internal consistency and test-retest reliability. RESULTS: The patient Concept 
Mapping resulted in 149 concepts which clustered into daily activities, emotions and
relationships. Eleven symptoms were identiﬁ ed from the literature. Expert content 
review led to item clariﬁ cation, removal (n  2) and addition of an item. Candidate 
items were drafted using predeﬁ ned criteria including simplicity and brevity. Both 
IRT and CFA assisted with item selection. The Symptoms scale factored into a
systemic and respiratory subscale (seven and three items, respectively) and the Impact 
scale covered impact on usual activities, emotional impact and impact on relationships 
(six, four and four items, respectively). Most sub-scales displayed good internal con-
sistency (Cronbach ¦Á q 0.8); the 3-item Respiratory sub-scale was poor (¦Á  0.50). 
Test-retest indicated high reliability (intraclass correlation coefﬁ cient 0.8 for all 
scales). CONCLUSIONS: These analyses provide evidence for the content validity and
reliability of the 24-item Flu-IIQ as a measure of symptom intensity and impact of 
inﬂ uenza.
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ANALYZING INPATIENT DATA FOR HEPATITIS PATIENTS
Sanders J
University of Louisville, Louisville, KY, USA
OBJECTIVES: To identify whether there are patterns and relationships between hepa-
titis and other patient values such as age, mortality rate, and certain procedures and
diagnoses. METHODS: We use data from the 2005 National Inpatient Sample. There 
are 2377 patients in the dataset with Hepatitis and a control group of 2400 patients
without hepatitis. We used the statistical data analysis program, SAS Enterprise Guide,
to examine the data with its methods of statistical analysis, one-way frequency, kernel 
density estimation, table analysis and linear and logistic regression. We used explor-
atory data analysis. RESULTS: The admission age is higher in hepatitis patients than 
it is in patients without hepatitis (9.5 years and 11.4 years respectively). The data also 
showed that there is a nine-fold increase in the mortality rate in patients who were
diagnosed with Hepatitis. There were more females admitted to the hospital with
hepatitis than males. Disorders of the liver or procedures involving the liver increased 
the likelihood of the patients suffering from Hepatitis. The relationship of procedure
and diagnosis codes to length of stay and total charges showed that if patients died,
their age and related co-morbidities such as pneumonia, viral hepatitis and chronic
non-alcoholic dependent liver disease had a great inﬂ uence on the length of stay and
total charges. CONCLUSIONS: The fact that the admission age is higher in patients 
with Hepatitis can be explained by the fact that Hepatitis is transmitted by blood or 
body ﬂ uid contact, which is more likely in older children. Since hepatitis affects the 
liver, it is not surprising that procedures and diagnoses involving the liver prevail in 
this model. Also, diseases involving internal organs can increase both the length of 
stay and the total charges as they are harder to treat.
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OF LIFE: A LONGITUDINAL ANALYSIS
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OBJECTIVES: Anti-tuberculosis (Anti-TB) treatment commonly results in adverse
drug reactions (ADRs). This study examined the impact of ADRs on health-related 
quality of life (HRQL) among patients with active TB. METHODS: HRQL was 
assessed at baseline and three months of the treatment using the Short-Form-36 
(SF-36). Information regarding ADRs to anti-TB treatment was obtained from elec-
tronic health charts. Linear regression was used to explore the impact of ADRs on 
the 3-month SF-36 outcomes. Logistic regression was performed to examine the cor-
relation between baseline SF-36 scores and occurrence of ADRs during the ﬁ rst three
months of treatment. Socio-demographic factors were adjusted for in all regression
models. RESULTS: A total of 89 patients with active TB were included. During the 
ﬁ rst three months of treatment, 21 (23.6%) patients developed major ADR(s) that led 
to discontinuation of treatment and/or additional interventions. When compared to 
those who never experienced ADRs, subjects who developed major ADR(s) scored
signiﬁ cantly lower on three SF-36 subscales: physical functioning (33.77 vs. 46.89, 
p  0.033), vitality (39.13 vs. 50.08, p  0.004), and mental health (39.16 vs. 50.28, 
p  0.025). Compared to those who had no recent ADRs, subjects who experienced
recent ADR(s) (within the past four weeks) had signiﬁ cant lower scores on the same
three subscales, and also the mental component summary score. Logistic regression
analyses suggested that baseline scores from the six SF-36 subscales (physical function-
ing, role-physical, vitality, role-emotional, social functioning, and mental health) and
the two summary components were signiﬁ cantly associated with a higher risk of 
developing ADR(s) during the ﬁ rst three months of treatment. CONCLUSIONS:
ADRs due to anti-TB treatment had substantial and profound impact on patients’ 
HRQL. Poor baseline HRQL might be associated with a higher risk of developing 
ADRs during treatment.
